{"id":"vbmcp-vbad-velcade","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL5624541","moleculeType":null,"molecularWeight":"384.25"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the proteasome, Velcade disrupts the normal functioning of cells, leading to cell death, particularly in cancer cells. This mechanism is particularly effective in multiple myeloma and mantle cell lymphoma.","oneSentence":"Velcade works by inhibiting the proteasome, a complex within cells that breaks down proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:15.800Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT00461747","phase":"PHASE3","title":"GEM05 for Patients With Multiple Myeloma Under 65 Years","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-03","conditions":"Multiple Myeloma","enrollment":390}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VBMCP/VBAD/Velcade","genericName":"VBMCP/VBAD/Velcade","companyName":"PETHEMA Foundation","companyId":"pethema-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Velcade, also known as VBMCP/VBAD, is a treatment for multiple myeloma, a type of blood cancer. It has been studied in clinical trials, including a phase III study comparing its effectiveness to Thalidomide/Dexamethasone in patients under 65 years old.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}